Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Lowered to “Strong Sell” at BidaskClub
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Saturday.
Several other analysts also recently commented on the company. Robert W. Baird raised their target price on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, April 24th. Leerink Swann upgraded Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $4.00 to $6.00 in a research note on Thursday, May 18th. Jefferies Group LLC restated a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Maxim Group reduced their target price on Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, April 25th. Finally, Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $8.75.
Shares of Achillion Pharmaceuticals (ACHN) traded up 1.03% during mid-day trading on Friday, hitting $3.94. The stock had a trading volume of 758,407 shares. The firm’s 50 day moving average price is $4.40 and its 200 day moving average price is $4.12. Achillion Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $9.49. The company’s market cap is $538.69 million.
Institutional investors have recently made changes to their positions in the stock. Deschutes Portfolio Strategy LLC boosted its position in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares during the last quarter. TradeLink Capital LLC acquired a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $132,000. Teza Capital Management LLC acquired a new position in shares of Achillion Pharmaceuticals during the first quarter valued at $131,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Achillion Pharmaceuticals during the first quarter valued at $138,000. 71.24% of the stock is currently owned by institutional investors and hedge funds.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.